Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  The Lancet

• Publication date

  2009-10-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(09)61259-9PMID 19815268
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?

  2009cited by this paper
• Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.

  2008cited by this paper
• Rationale for early intervention with immunomodulatory treatments

  2008cited by this paper
• Clinically isolated syndrome: the rationale for early treatment

  2008cited by this paper
• Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

  2008cited by this paper
• Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

  2008cited by this paper
• Future therapies in multiple sclerosis

  2008cited by this paper
• Clinically isolated syndromes

  2007cited by this paper
• Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial

  2007cited by this paper
• The contribution of demyelination to axonal loss in multiple sclerosis.

  2006cited by this paper
• Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

  2006cited by this paper
• Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

  2006cited by this paper
• Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.

  2006cited by this paper
• Early treatment

  2006cited by this paper
• Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management.

  2005cited by this paper
• Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis.

  2005cited by this paper
• Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

  2005cited by this paper
• Cortical demyelination and diffuse white matter injury in multiple sclerosis.

  2005cited by this paper
• Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

  2004cited by this paper
• Interferon beta-1b in secondary progressive MS

  2004cited by this paper
• Simple and complex movement‐associated functional MRI changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis

  2004cited by this paper
• The Relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis

  2004cited by this paper
• High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial.

  2003cited by this paper
• Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

  2002cited by this paper
• Interferon β‐1a for early multiple sclerosis: CHAMPS trial subgroup analyses

  2002cited by this paper
• Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

  2002cited by this paper
• Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability.

  2001cited by this paper
• Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

  2001cited by this paper
• European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

  2001cited by this paper
• The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.

  2000cited by this paper
• Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

  2000cited by this paper
• Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

  1998cited by this paper
• Axonal transection in the lesions of multiple sclerosis.

  1998cited by this paper
• Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis

  1998cited by this paper
• Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis

  1997cited by this paper
• Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

  1991cited by this paper
• A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.

  1987cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper

• A Prospective Study of Individuals at Risk of Multiple Sclerosis Informs the Design of Primary Prevention Studies.

  2026cites this paper
• Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1

  2025cites this paper
• Evaluation of Early Initiation of Disease-Modifying Treatment for Patients with Multiple Sclerosis Within a Real-World Population for Long-Term Outcomes

  2025cites this paper
• Advances in Therapeutics Research for Demyelinating Diseases

  2025cites this paper
• HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis

  2025cites this paper
• From diagnosis to treatment: exploring the mechanisms underlying optic neuritis in multiple sclerosis

  2025cites this paper
• Choosing initial MS therapy; personal, disease, and medication factors

  2025influential citation
• Management of disease-modifying therapies in multiple sclerosis and comorbid rheumatoid arthritis

  2025cites this paper
• Effect of Different Treatments on Retinal Thickness Changes in Patients With Multiple Sclerosis: A Review

  2025cites this paper
• Exploring the Pathophysiology, Diagnosis, and Treatment Options of Multiple Sclerosis.

  2025cites this paper
• Breaking the assumption: Disease-modifying therapy efficacy and relapse severity in relapsing-remitting multiple sclerosis.

  2025cites this paper
• The astrocyte-produced growth factor HB-EGF limits autoimmune CNS pathology

  2024cites this paper
• Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023.

  2024cites this paper
• Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis

  2024cites this paper
• An overview on disease modifying and symptomatic drug treatments for multiple sclerosis

  2024cites this paper
• Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort

  2024cites this paper
• Radiologically isolated syndromes: to treat or not to treat?

  2024cites this paper
• Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis

  2024cites this paper
• Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines.

  2024cites this paper
• Documento de consenso de la Sociedad Española de Neurología sobre el tratamiento de la esclerosis múltiple y manejo holístico del paciente 2023

  2024cites this paper
• Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders

  2024cites this paper
• Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis

  2024cites this paper
• Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders.

  2023cites this paper
• Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event

  2023cites this paper
• Evidence-based management of optic neuritis

  2023cites this paper
• Reconsidering the route of drug delivery in refractory multiple sclerosis: Toward a more effective drug accumulation in the central nervous system

  2023cites this paper
• Early Treatment for Multiple Sclerosis

  2023cites this paper
• Real-life evaluation of the 2017 McDonald criteria for relapsing–remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time-to-diagnosis

  2023cites this paper
• Lesion location across diagnostic regions in multiple sclerosis

  2023cites this paper
• Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease

  2023cites this paper
• Neue Therapieansätze bei Multipler Sklerose inkl. Stellenwert älterer Präparate

  2023cites this paper
• Safety and Monitoring of the treatment with Disease-Modifying Therapies for Multiple Sclerosis.

  2022cites this paper
• Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives

  2022cites this paper
• Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study

  2022cites this paper
• Controversias en neuroinmunología: esclerosis múltiple, vacunación, SARS-CoV-2 y otros dilemas

  2022cites this paper
• A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis

  2022cites this paper
• Treatment of Multiple Sclerosis

  2022cites this paper
• The need for a strategic therapeutic approach: multiple sclerosis in check

  2022cites this paper
• The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome.

  2022cites this paper
• Pathways to cures for multiple sclerosis: A research roadmap

  2022cites this paper
• Percentage brain volume change in multiple sclerosis mainly reflects white matter and cortical volume

  2022cites this paper
• Blood Metabolomics May Discriminate a Sub-Group of Patients with First Demyelinating Episode in the Context of RRMS with Increased Disability and MRI Characteristics Indicative of Poor Prognosis

  2022cites this paper
• The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy

  2022cites this paper
• The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review

  2021cites this paper
• Aggressive multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM.

  2021cites this paper
• Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)

  2021cites this paper
• The role of immune semaphorins in the pathogenesis of multiple sclerosis: Potential therapeutic targets.

  2021cites this paper
• Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS

  2021cites this paper
• Real world prognosis in MS: does early versus late diagnosis matter?

  2021cites this paper
• Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network

  2021cites this paper
• Predicting conversion to multiple sclerosis in patients with radiologically isolated syndrome: a retrospective study

  2021cites this paper
• Prediction in treatment outcomes in multiple sclerosis: challenges and recent advances

  2021cites this paper
• The Increasing Role of Kappa Free Light Chains in the Diagnosis of Multiple Sclerosis

  2021cites this paper
• Immunosuppression in Multiple Sclerosis and Other Neurologic Disorders.

  2021cites this paper
• Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression

  2021cites this paper
• Effect of switching glatiramer acetate formulation from 20 mg daily to 40 mg three times weekly on immune function in multiple sclerosis

  2021cites this paper
• Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

  2021cites this paper
• Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study

  2021cites this paper
• Multiple Sclerosis Diagnostic Criteria

  2021cites this paper
• Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)

  2021cites this paper
• Early diagnosis and treatment of multiple sclerosis

  2021cites this paper
• Multiple sclerosis and subclinical neuropathology in healthy individuals with familial risk: A scoping review of MRI studies

  2021cites this paper
• Approach to optic neuritis: An update

  2021cites this paper
• Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines.

  2020cites this paper
• Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.

  2020cites this paper
• Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis

  2020cites this paper
• A novel decision tree approach to predict the probability of conversion to multiple sclerosis in Iranian patients with optic neuritis.

  2020cites this paper
• Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis

  2020cites this paper
• The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis.

  2020cites this paper
• Systematic review and meta-analysis of the development of multiple sclerosis in clinically isolated syndrome

  2020cites this paper
• Long-term drug treatment in multiple sclerosis: safety success and concerns

  2020cites this paper
• A systematic review of the effect of omega-3 supplements on meibomian gland dysfunction

  2020cites this paper
• Neuroinflammatory and Demyelinating Disorders of Childhood

  2020cites this paper
• Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis

  2020cites this paper
• Validity of the McDonald criteria in predicting second events in multiple sclerosis.

  2020cites this paper
• AI in Radiology: Where are we today in Multiple Sclerosis Imaging? KI in der Radiologie: Wo stehen wir in der MS-Bildgebung?

  2020cites this paper
• Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS.

  2020cites this paper
• Evolution of Cortical and White Matter Lesion Load in Early-Stage Multiple Sclerosis: Correlation With Neuroaxonal Damage and Clinical Changes

  2020cites this paper
• Application of the 2017 McDonald criteria for the diagnosis of multiple sclerosis after a first demyelinating event in patients from Argentina.

  2020cites this paper
• Multipl Sklerozlu Hastaların Tedavi Yönetimi ve Hemşirelik Yaklaşımları

  2020cites this paper
• Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations

  2020cites this paper
• Kopfschmerzen bei Multipler Sklerose

  2020cites this paper
• Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis?

  2020cites this paper
• Pathophysiologic Insights from Biomarker Studies in Neurological Disorders

  2020cites this paper
• MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice

  2020cites this paper
• Evaluation of diagnosis and treatment practices of Brazilian neurologists among patients with multiple sclerosis

  2020cites this paper
• Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity

  2020cites this paper
• The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.

  2020cites this paper
• Optic neuritis and neuromyelitis optica - clinical and genetic aspects

  2019cites this paper
• Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options

  2019cites this paper
• The Evolving Mechanisms of Action of Glatiramer Acetate.

  2019cites this paper
• Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis

  2019cites this paper
• Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

  2019cites this paper
• Drug Treatment of Clinically Isolated Syndrome

  2019cites this paper
• An update on the safety of treating relapsing-remitting multiple sclerosis

  2019cites this paper
• Models and treatments for traumatic optic neuropathy and demyelinating optic neuritis

  2019cites this paper
• Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★.

  2019cites this paper
• Clinically Isolated Syndrome and Early Relapsing Multiple Sclerosis.

  2019cites this paper
• Improving Outcomes in Pediatric Multiple Sclerosis: Current and Emerging Treatments

  2019cites this paper
• Assessing the risk of multiple sclerosis disease-modifying therapies

  2019cites this paper